Recent study in the Journal of Urology shows PredicineCARE urine-based liquid biopsy test provides non-invasive molecular profiling for patients with bladder cancer

Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer.

The publications can be found online at: (HERE)

Leave a Reply

18 − seven =